📊 CBIH Key Takeaways
Investment Thesis
Cannabis Bioscience International is a fundamentally distressed company with severe financial deterioration across all key metrics. The company exhibits negative stockholders' equity of $1.4M, massive operating losses, critically low liquidity (0.02x current ratio), and minimal revenue generation ($77.5K) insufficient to cover any operating expenses. The combination of insolvency, negative cash flows, and inability to generate profits makes this an extremely high-risk investment unsuitable for most portfolios.
CBIH Strengths
- High gross margin of 75.9% indicates strong product-level economics if revenue could scale
- Year-over-year revenue growth of 21.8% shows some demand for services
- Relatively low total debt of $291.2K in absolute terms
CBIH Risks
- Negative stockholders' equity of -$1.4M indicates technical insolvency and potential total loss of equity value
- Critical liquidity crisis with current ratio of 0.02x and only $132 in cash against $1.4M in liabilities
- Massive operating losses (-$170.7K) and negative free cash flow (-$4.7M) with negligible revenue ($77.5K) unable to sustain operations
- Severely negative operating margin (-220.3%) and net margin (-257.7%) indicating structural unprofitability
- Capital expenditure of $4.6M against only $77.5K in revenue demonstrates unsustainable spending patterns
- No insider activity in last 90 days suggesting potential loss of management confidence
Key Metrics to Watch
- Cash balance trend and runway to insolvency
- Revenue growth sustainability and operating expense reduction initiatives
- Debt refinancing or capital restructuring announcements to address negative equity
CBIH Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CBIH Profitability Ratios
CBIH vs Healthcare Sector
How Cannabis Bioscience International Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CBIH Balance Sheet & Liquidity
CBIH 5-Year Financial Trend
5-Year Trend Summary: Cannabis Bioscience International Holdings, Inc.'s revenue has remained relatively flat over the 5-year period, with a 4% decline. The most recent EPS of $0.00 indicates the company is currently unprofitable.
CBIH Growth Metrics (YoY)
CBIH Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $53.3K | -$76.3K | $0.00 |
| Q1 2026 | $24.2K | -$76.3K | $0.00 |
| Q1 2025 | $72.8K | -$76.3K | $0.00 |
| Q3 2024 | $36.4K | -$124.4K | $0.00 |
| Q2 2024 | $63.7K | -$124.4K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CBIH Capital Allocation
CBIH SEC Filings
Access official SEC EDGAR filings for Cannabis Bioscience International Holdings, Inc. (CIK: 0001411057)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CBIH
What is the AI rating for CBIH?
Cannabis Bioscience International Holdings, Inc. (CBIH) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CBIH's key strengths?
High gross margin of 75.9% indicates strong product-level economics if revenue could scale. Year-over-year revenue growth of 21.8% shows some demand for services.
What are the risks of investing in CBIH?
Negative stockholders' equity of -$1.4M indicates technical insolvency and potential total loss of equity value. Critical liquidity crisis with current ratio of 0.02x and only $132 in cash against $1.4M in liabilities.
What is CBIH's revenue and growth?
Cannabis Bioscience International Holdings, Inc. reported revenue of $77.5K.
Does CBIH pay dividends?
Cannabis Bioscience International Holdings, Inc. does not currently pay dividends.
Where can I find CBIH SEC filings?
Official SEC filings for Cannabis Bioscience International Holdings, Inc. (CIK: 0001411057) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CBIH's EPS?
Cannabis Bioscience International Holdings, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.